| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Ludwig Institute for Cancer Research (Sydney Branch), University of Sydney, New South Wales 2006, Australia [G. J. M., E. A. M.]; Departments of Haematology and Medical Oncology, Royal Melbourne Hospital, Victoria 3050, Australia [R. M. F.]; and Department of Physiological Chemistry, University of Umeå, S-901 87 Umeå, Sweden [L. T.]
Ribonucleotide reductase catalyzes the first unique, rate-limiting step in DNA synthesis; both its large (M1) and small (M2) subunits are necessary for activity. While direct studies of M2 expression have previously shown a tight correlation with S phase, the kinetic features of M1-expressing cells have remained ill defined. Therefore we have, using immunofluorescence flow cytometry, analyzed changes in whole cell M1 levels and DNA content during various cell cycle and differentiation events.
In asynchronous cultures M1 levels are sustained throughout the cell cycle, including G1 phase when M2 levels and ribonucleotide reductase catalytic activity are known to be very low. In contrast M1 is virtually absent from quiescent lymphocytes but is expressed following mitogen stimulation, shortly before S phase cells appear. M1 declines to low levels in "plateau phase" cultures, the major reduction occurring in cells with 2n (G0/G1) DNA content. HL-60 promyelocytic leukemia cells, induced into either myeloid or monocyte-macrophage differentiation, show a similar marked decrease in M1 levels concomitant with the cessation of cell division.
We conclude that the M1 subunit of ribonucleotide reductase is constitutively expressed by cycling cells. It is acquired during stimulated transition from G0 to G1 and is lost during exit to G0 or terminal differentiation. This pattern of expression suggests that determination of cellular M1 content may be useful in distinguishing proliferating (including G1) and quiescent (including G0) cells in vivo.
1 Present address: Department of Physiological Chemistry, University of Umeå, S-901 87 Umeå, Sweden. To whom requests for reprints should be addressed.
2 Present address: Garvan Institute for Medical Research, St. Vincent's Hospital, Darlinghurst, New South Wales 2010, Australia.
Received 11/16/87. Revised 2/12/88. Revised 5/18/88. Accepted 6/ 8/88.
This article has been cited by other articles:
|
|
 |
|
  S.-O. Kim, J.-Y. Jeong, M.-R. Kim, H.-J. Cho, J.-Y. Ju, Y.-S. Kwon, I.-J. Oh, K.-S. Kim, Y.-I. Kim, S.-C. Lim, et al. Efficacy of Gemcitabine in Patients with Non-Small Cell Lung Cancer According to Promoter Polymorphisms of the Ribonucleotide Reductase M1 Gene Clin. Cancer Res., May 15, 2008; 14(10): 3083 - 3088. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Xu, J. L. Page, J. A. Surtees, H. Liu, S. Lagedrost, Y. Lu, R. Bronson, E. Alani, A. Yu. Nikitin, and R. S. Weiss Broad Overexpression of Ribonucleotide Reductase Genes in Mice Specifically Induces Lung Neoplasms Cancer Res., April 15, 2008; 68(8): 2652 - 2660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gautam and G. Bepler Suppression of Lung Tumor Formation by the Regulatory Subunit of Ribonucleotide Reductase. Cancer Res., July 1, 2006; 66(13): 6497 - 6502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hakansson, A. Hofer, and L. Thelander Regulation of Mammalian Ribonucleotide Reduction and dNTP Pools after DNA Damage and in Resting Cells J. Biol. Chem., March 24, 2006; 281(12): 7834 - 7841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. P. Jordheim, O. Guittet, M. Lepoivre, C. M. Galmarini, and C. Dumontet Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells Mol. Cancer Ther., August 1, 2005; 4(8): 1268 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Dong, Y. Liu, and J.-T. Zhang Regulation of ribonucleotide reductase M2 expression by the upstream AUGs Nucleic Acids Res., May 11, 2005; 33(8): 2715 - 2725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. P. Lin, M. F. Belcourt, J. G. Cory, and A. C. Sartorelli Stable Suppression of the R2 Subunit of Ribonucleotide Reductase by R2-targeted Short Interference RNA Sensitizes p53(-/-) HCT-116 Colon Cancer Cells to DNA-damaging Agents and Ribonucleotide Reductase Inhibitors J. Biol. Chem., June 25, 2004; 279(26): 27030 - 27038. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Bepler, S. Sharma, A. Cantor, A. Gautam, E. Haura, G. Simon, A. Sharma, E. Sommers, and L. Robinson RRM1 and PTEN As Prognostic Parameters for Overall and Disease-Free Survival in Patients With Non-Small-Cell Lung Cancer J. Clin. Oncol., May 15, 2004; 22(10): 1878 - 1885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wadler, D. Makower, C. Clairmont, P. Lambert, K. Fehn, and M. Sznol Phase I and Pharmacokinetic Study of the Ribonucleotide Reductase Inhibitor, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, Administered by 96-Hour Intravenous Continuous Infusion J. Clin. Oncol., May 1, 2004; 22(9): 1553 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Zhou, X. Liu, X. Mo, L. Xue, D. Darwish, W. Qiu, J. Shih, E. B. Hwu, F. Luh, and Y. Yen The Human Ribonucleotide Reductase Subunit hRRM2 Complements p53R2 in Response to UV-Induced DNA Repair in Cells with Mutant p53 Cancer Res., October 15, 2003; 63(20): 6583 - 6594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-Y. Cao, Y. Lee, N.-P. Feng, K. Xiong, H. Jin, M. Wang, A. Vassilakos, S. Viau, J. A. Wright, and A. H. Young Adenovirus-Mediated Ribonucleotide Reductase R1 Gene Therapy of Human Colon Adenocarcinoma Clin. Cancer Res., October 1, 2003; 9(12): 4553 - 4561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Chabes, C. M. Pfleger, M. W. Kirschner, and L. Thelander Mouse ribonucleotide reductase R2 protein: A new target for anaphase-promoting complex-Cdh1-mediated proteolysis PNAS, April 1, 2003; 100(7): 3925 - 3929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Xue, B. Zhou, X. Liu, W. Qiu, Z. Jin, and Y. Yen Wild-Type p53 Regulates Human Ribonucleotide Reductase by Protein-Protein Interaction with p53R2 as well as hRRM2 Subunits Cancer Res., March 1, 2003; 63(5): 980 - 986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Gandhi, W. Plunkett, M. Du, M. Ayres, and E. H. Estey Prolonged Infusion of Gemcitabine: Clinical and Pharmacodynamic Studies During a Phase I Trial in Relapsed Acute Myelogenous Leukemia J. Clin. Oncol., February 1, 2002; 20(3): 665 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Olakanmi, B. E. Britigan, and L. S. Schlesinger Gallium Disrupts Iron Metabolism of Mycobacteria Residing within Human Macrophages Infect. Immun., October 1, 2000; 68(10): 5619 - 5627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Davenport and J. S. Pagano Expression of EBNA-1 mRNA Is Regulated by Cell Cycle during Epstein-Barr Virus Type I Latency J. Virol., April 1, 1999; 73(4): 3154 - 3161. [Abstract] [Full Text]
|
|
|
|
|
|
E. Johansson, K. Hjortsberg, and L. Thelander Two YY-1-binding Proximal Elements Regulate the Promoter Strength of the TATA-less Mouse Ribonucleotide Reductase R1 Gene J. Biol. Chem., November 6, 1998; 273(45): 29816 - 29821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Filatov, S. Bjorklund, E. Johansson, and L. Thelander Induction of the Mouse Ribonucleotide Reductase R1 and R2 Genes in Response to DNA Damage by UV Light J. Biol. Chem., September 27, 1996; 271(39): 23698 - 23704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R J Duronio and P H O'Farrell Developmental control of the G1 to S transition in Drosophila: cyclin Eis a limiting downstream target of E2F. Genes & Dev., June 15, 1995; 9(12): 1456 - 1468. [Abstract] [PDF]
|
|
|
|
|
|
S J Elledge and R W Davis Two genes differentially regulated in the cell cycle and by DNA-damaging agents encode alternative regulatory subunits of ribonucleotide reductase. Genes & Dev., May 1, 1990; 4(5): 740 - 751. [Abstract] [PDF]
|
|
|
|
|
|
A. Chabes and L. Thelander Controlled Protein Degradation Regulates Ribonucleotide Reductase Activity in Proliferating Mammalian Cells during the Normal Cell Cycle and in Response to DNA Damage and Replication Blocks J. Biol. Chem., June 2, 2000; 275(23): 17747 - 17753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Guittet, P. Hakansson, N. Voevodskaya, S. Fridd, A. Graslund, H. Arakawa, Y. Nakamura, and L. Thelander Mammalian p53R2 Protein Forms an Active Ribonucleotide Reductase in Vitro with the R1 Protein, Which Is Expressed Both in Resting Cells in Response to DNA Damage and in Proliferating Cells J. Biol. Chem., October 26, 2001; 276(44): 40647 - 40651. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
